Učitavanje...
Patient‐Reported Outcomes Predict Progression‐Free Survival of Patients with Advanced Breast Cancer Treated with Abemaciclib
BACKGROUND: Abemaciclib is a CDK4/6 inhibitor used to treat hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer. The prognostic value of patient‐reported outcomes (PROs) has been minimally explored for treatment outcomes with CDK4/6 inhibitors. The per...
Spremljeno u:
| Izdano u: | Oncologist |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley & Sons, Inc.
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8265347/ https://ncbi.nlm.nih.gov/pubmed/33914991 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13806 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|